BioSpace News Archive

Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers.

With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.

The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.

Dante Labs announced today the appointment of Mark Van Oene as a member of its Board of Directors.

ITOCO INC. (OTC PINK:ITMC) is pleased to announce that Mr. Erik Gordillo Enamorado has joined ITOCO as Project Coordinator Carbon Credits and Chief Agricultural Liaison.

Sight Sciences, Inc., a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world’s most prevalent eye diseases, announced publication in Clinical Ophthalhmology of favorable 24-month outcomes from a single center open-label study of the OMNI® Surgical System conducted in Germany.

AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib), an oral, selective and reversible JAK inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Q BioMed Inc. is expected to receive a patent in Korea, adding to the already issued patents in Canada and Japan .

InSphero AG , the pioneer of 3D cell-based assay technology, today announced that the company is making their proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight™ Human Liver Microtissues.

Stryker has announced the launch of its T2 Alpha Femur Retrograde Nailing System.